PL1805164T3 - Pochodne 6-(pirydynylo)-4-pirymidonu jako inhibitory kinazy 1 białka tau - Google Patents

Pochodne 6-(pirydynylo)-4-pirymidonu jako inhibitory kinazy 1 białka tau

Info

Publication number
PL1805164T3
PL1805164T3 PL05790292T PL05790292T PL1805164T3 PL 1805164 T3 PL1805164 T3 PL 1805164T3 PL 05790292 T PL05790292 T PL 05790292T PL 05790292 T PL05790292 T PL 05790292T PL 1805164 T3 PL1805164 T3 PL 1805164T3
Authority
PL
Poland
Prior art keywords
pyrimidone
derivates
pyridinyl
inhibitors
protein kinase
Prior art date
Application number
PL05790292T
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Kenji Fukunaga
Toshiyuki Kohara
Fumiaki Uehara
Shinsuke Hiki
Satoshi Yokoshima
Original Assignee
Mitsubishi Tanabe Pharma Corp
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Sanofi Aventis filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PL1805164T3 publication Critical patent/PL1805164T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL05790292T 2004-09-29 2005-09-29 Pochodne 6-(pirydynylo)-4-pirymidonu jako inhibitory kinazy 1 białka tau PL1805164T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004313115 2004-09-29
EP05790292A EP1805164B9 (en) 2004-09-29 2005-09-29 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
PCT/JP2005/018497 WO2006036015A2 (en) 2004-09-29 2005-09-29 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
PL1805164T3 true PL1805164T3 (pl) 2011-07-29

Family

ID=35848411

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05790292T PL1805164T3 (pl) 2004-09-29 2005-09-29 Pochodne 6-(pirydynylo)-4-pirymidonu jako inhibitory kinazy 1 białka tau

Country Status (25)

Country Link
US (1) US8129377B2 (pl)
EP (3) EP2261224A3 (pl)
JP (1) JP5186213B2 (pl)
KR (1) KR20070057931A (pl)
CN (1) CN101048397A (pl)
AR (1) AR051823A1 (pl)
AT (1) ATE499356T1 (pl)
AU (1) AU2005288045B2 (pl)
BR (1) BRPI0515851A (pl)
CA (1) CA2581179A1 (pl)
CY (1) CY1112326T1 (pl)
DE (1) DE602005026546D1 (pl)
DK (1) DK1805164T3 (pl)
EA (1) EA013004B1 (pl)
ES (1) ES2359071T3 (pl)
IL (1) IL182223A0 (pl)
MX (1) MX2007003722A (pl)
NO (1) NO20072214L (pl)
NZ (1) NZ554722A (pl)
PL (1) PL1805164T3 (pl)
PT (1) PT1805164E (pl)
SI (1) SI1805164T1 (pl)
TW (1) TWI354669B (pl)
WO (1) WO2006036015A2 (pl)
ZA (1) ZA200703383B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
CA2661334C (en) * 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
JPWO2011062194A1 (ja) 2009-11-18 2013-04-04 武田薬品工業株式会社 アミノピリジン誘導体
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
CN116782894A (zh) * 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
IL160701A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
EP1427720B1 (en) 2001-09-21 2009-03-04 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454908B1 (en) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
EA013004B1 (ru) 2010-02-26
TWI354669B (en) 2011-12-21
WO2006036015A2 (en) 2006-04-06
EP2266969A3 (en) 2011-02-16
TW200626573A (en) 2006-08-01
EP2261224A3 (en) 2011-02-16
AU2005288045A2 (en) 2008-05-29
ZA200703383B (en) 2009-05-27
US8129377B2 (en) 2012-03-06
WO2006036015A3 (en) 2006-06-01
EP1805164B1 (en) 2011-02-23
BRPI0515851A (pt) 2008-08-12
CY1112326T1 (el) 2015-12-09
AU2005288045A1 (en) 2006-04-06
SI1805164T1 (sl) 2011-05-31
US20090239864A1 (en) 2009-09-24
KR20070057931A (ko) 2007-06-07
AR051823A1 (es) 2007-02-14
EP2266969A2 (en) 2010-12-29
EA200700756A1 (ru) 2007-10-26
NO20072214L (no) 2007-06-12
DE602005026546D1 (de) 2011-04-07
JP5186213B2 (ja) 2013-04-17
DK1805164T3 (da) 2011-05-16
AU2005288045B2 (en) 2011-08-18
JP2008514587A (ja) 2008-05-08
IL182223A0 (en) 2007-09-20
CA2581179A1 (en) 2006-04-06
ATE499356T1 (de) 2011-03-15
EP1805164A2 (en) 2007-07-11
CN101048397A (zh) 2007-10-03
EP2261224A2 (en) 2010-12-15
EP1805164B9 (en) 2011-09-07
NZ554722A (en) 2010-07-30
PT1805164E (pt) 2011-04-11
ES2359071T3 (es) 2011-05-18
MX2007003722A (es) 2007-05-23

Similar Documents

Publication Publication Date Title
IL182223A0 (en) 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
IL179613A0 (en) Compounds and compositions as protein kinase inhibitors
EP1713806A4 (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE
IL182687A0 (en) Compounds and compositions as protein kinase inhibitors
IL181047A0 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
ZA200710343B (en) Bicyclic derivatives as p38 kinase inhibitors
IL189264A0 (en) p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME
IL189356A0 (en) p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME
ZA200701281B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
IL192298A0 (en) Heterocyclic janus kinase 3 inhibitors
IL183276A0 (en) Kinase inhibitors
ZA200709269B (en) Protein kinase inhibitors
IL189381A0 (en) P38 map kinase inhibitors and methods for using the same
IL199378A0 (en) 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
IL189382A0 (en) p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1765820A4 (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES
ZA200607648B (en) Kinase inhibitors
ZA200703130B (en) Compounds and compositions as protein kinase inhibitors
SI2476667T1 (sl) Aminoheteroarilne spojine kot inhibitorji protein-kinaze
ZA200700923B (en) Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
EP1689394A4 (en) AMSTNOSUBSTITUATED PYRIDINYLMETHANONE COMPOUNDS FOR THE TREATMENT OF KINASE DISORDERS